Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 23%
Buy 8%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health is experiencing robust growth, evidenced by a remarkable 70% year-over-year subscriber growth in Q4, alongside a diversified service portfolio that reduces concentration risk compared to direct-to-consumer peers focused solely on weight loss. The company's expansion into international markets, coupled with the strategic acquisition of Zava, positions Hims favorably for incremental revenue growth, particularly in its weight-loss segment as it prepares to offer additional drugs currently in development. Furthermore, the anticipated normalization of revenue in conjunction with subscriber growth suggests a favorable outlook as the business transitions through this period of change.

Bears say

Hims & Hers Health is experiencing a significant slowdown in revenue growth, with 4Q:25 results disappointing and a weaker than expected 1Q:26 revenue guidance contributing to a negative outlook. Revenue estimates for F2027E have decreased from $3.7 billion and $535 million in EBITDA to $3.1 billion and $404 million, reflecting a decline in performance expectations. Additionally, the company faces increased legal and regulatory risks, further complicating its financial trajectory.

HIMS has been analyzed by 13 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 8% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 13 analysts, HIMS has a Hold consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.